Erasca posts Q1 net loss of $183.4M; cash $408.5M; advances ERAS-0015 with robust early data

Erasca, Inc.

• Net loss of $183.4M ($0.60 per share) vs $31.0M loss a year ago; includes $150M in-process R&D charge for license expansion.
• Cash and securities of $408.5M as of Mar 31, 2026, expected to fund ops into H2 2028; completed $258.8M public offering in Jan.
• ERAS-0015 dose escalation showed robust responses in KRAS G12X NSCLC and PDAC with favorable safety; no TRAE discontinuations.
• Monotherapy expansion and combo with panitumumab initiated ahead of schedule; data expected H1 2027.
• Entered CTCSA with Merck for ERAS-0015 + KEYTRUDA combo; also with Tango for PRMT5 inhibitor combo.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.